Clinical trials
Inflammation trials in Iran
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 8 |
| Active, not recruiting | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Isfahan University of Medical Sciences | 3 |
| Shahid Beheshti University of Medical Sciences | 3 |
| Ahvaz Jundishapur University of Medical Sciences | 2 |
| Fasa University of Medical Sciences | 2 |
| Mashhad University of Medical Sciences | 2 |
| National Nutrition and Food Technology Institute | 2 |
| Shahid Beheshti University | 2 |
| Shiraz University of Medical Sciences | 2 |
| Darya Chamani | 1 |
| Ilam University of Medical Sciences | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammation | 26 |
| Malnutrition | 5 |
| Cardiovascular Diseases | 2 |
| Critical Illness | 2 |
| Infections | 2 |
| Multiple Organ Failure | 2 |
| Vitamin D Deficiency | 2 |
| Acne Vulgaris | 1 |
| Atherosclerosis | 1 |
| Breast Neoplasms | 1 |
Trials
Showing 26 to 26 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.